Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

The firm's full and mini gastrointestinal panel tests can now be used with fecal swab samples to detect pathogen nucleic acids.

The Netherlands-based company will develop a low-cost, rapid point-of-care test using its Visualization by Infrared PEptide Reaction (VIPER) technology.

The Colorado firm is expanding its partnerships, outreach efforts, technology applications, and sales force for its oncology screening and monitoring test business.

The certification applies to Gradientech's Class B QuickMIC GN AST panel for Gram-negative bacteria, along with the entire diagnostic platform.

The companies will use the Phase I Small Business Innovation Research (SBIR) grant to support the development of a urine-based ELISA to inform treatment decisions.

The company is developing blood tests for chronic diseases using artificial intelligence models and a database of more than 400,000 tissue samples.

The partners will begin with work on a cortisol biosensor that can be used for stress and metabolic health testing.

The company's Dragonfly instrument uses a proprietary sample preparation method and isothermal amplification to diagnose a variety of infectious diseases.

The projects include the development of rapid diagnostic tests for tuberculosis, Strongyloides stercoralis, and malaria.

The high-throughput antigen test includes all four dengue virus serotypes and returns results in about 18 minutes.

Total revenues for the three months ended Sept. 30 were $3.56 billion, up from $3.28 billion in the third quarter of 2024 and matching the consensus Wall Street estimate.